NCT00860873已完成3 期
Randomized Study of Two Dosage Forms (Oral Powder and Capsule) of "Chondroitin + Glucosamine Sulfate" Produced by the Laboratory EMS When Compared to the Product Condroflex (Oral Powder and Capsules) Produced by Laboratory Zodiac in the Treatment of Osteoarthrosis.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 280
- 试验地点
- 2
- 主要终点
- Decrease in pain.
研究概览
简要总结
This study objective is to check the non-inferiority of the 2 formulations produced by EMS when compared with the same substances and pharmaceuticals forms of the product Condroflex (Zodiac), by promoting the relief of osteoarthrosis symptoms such as pain, stiffness and functional capacity that will be periodically measured by using the "Visual Analog Scale" of pain (VAS) and the questionnaire of Lequesne.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 30 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients who agree with all aspects of the study and sign the Informed Consent;
- •Patients of both sexes;
- •Age above 30 years;
- •Clinical and radiological diagnosis of osteoarthritis;
- •Osteoarthritis in grades 1-2;
- •Patients who are conducting medical treatment and that, for trial of Investigator, is eligible for the study.
排除标准
- •Patients with a history of trauma clinically significant;
- •Patients who underwent surgery on joints affected;
- •Coexistence of diseases that might impede the successful conclusion of the trial (rheumatism and others);
- •Pregnant patients and / or breastfeeding;
- •Patients with phenylketonuria;
- •Patients with clinical diagnosis of severe renal failure;
- •Patients with clinical diagnosis of severe liver disease;
- •Patients with clinical diagnosis of clotting disorders;
- •Patients who are being treated with anti-aggregating and / or anticoagulants;
- •Patients with sensitive components of the formula;
- •Patients with emotional disorders that interfere with the capture of data;
- •Patients who do not agree with the purposes of the study and did not sign the Informed Consent.
结局指标
主要结局
Decrease in pain.
时间窗: V0 (Screening); V1 (Inclusion); V2 (2 weeks); V3 (4 weeks); V4 (8 weeks); V5 (12 weeks); V6 (24 weeks).
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the KneeOsteoarthritis of the KneeNCT01133613Stryker Biotech51
已完成
1 期
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy PeopleHealthy VolunteersType 2 DiabetesNCT05227196Novo Nordisk A/S546
已完成
1 期
A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release FormulationsSchizophreniaNCT00796471Johnson & Johnson Pharmaceutical Research & Development, L.L.C.35
已完成
2 期
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseNCT00742248Chiesi Farmaceutici S.p.A.54
已完成
1 期
Bioequivalence Study to Compare Metformin / Vildagliptin Versus Galvumet®Fed ConditionsNCT06073600Reseach Laboratory of Clinical and Experimental Pharmacology18